JP2017532313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532313A5 JP2017532313A5 JP2017514888A JP2017514888A JP2017532313A5 JP 2017532313 A5 JP2017532313 A5 JP 2017532313A5 JP 2017514888 A JP2017514888 A JP 2017514888A JP 2017514888 A JP2017514888 A JP 2017514888A JP 2017532313 A5 JP2017532313 A5 JP 2017532313A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- amino acids
- acid residues
- sequence corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185138.6 | 2014-09-17 | ||
| EP14185138 | 2014-09-17 | ||
| PCT/EP2015/071359 WO2016042093A1 (en) | 2014-09-17 | 2015-09-17 | Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532313A JP2017532313A (ja) | 2017-11-02 |
| JP2017532313A5 true JP2017532313A5 (enExample) | 2018-10-04 |
| JP6783754B2 JP6783754B2 (ja) | 2020-11-11 |
Family
ID=51542245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514888A Active JP6783754B2 (ja) | 2014-09-17 | 2015-09-17 | 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11279771B2 (enExample) |
| EP (1) | EP3194447B1 (enExample) |
| JP (1) | JP6783754B2 (enExample) |
| CN (1) | CN106687482B (enExample) |
| ES (1) | ES2905085T3 (enExample) |
| WO (1) | WO2016042093A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2016193380A1 (en) | 2015-06-02 | 2016-12-08 | Novo Nordisk A/S | Insulins with polar recombinant extensions |
| MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
| CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| WO2017194597A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| JP6987424B2 (ja) | 2016-05-11 | 2022-01-05 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを洗浄および／または消毒する方法 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| AU2017376839B2 (en) * | 2016-12-16 | 2021-01-14 | IBMC (Instituto de Biologia Molecular e Cellular) | Thrombin inhibitors for treatment of stroke and related coagulative disorders |
| JP2020513019A (ja) | 2017-04-05 | 2020-04-30 | ノヴォ ノルディスク アー／エス | オリゴマー伸長インスリン−Ｆｃコンジュゲート |
| CN117285632A (zh) * | 2022-06-17 | 2023-12-26 | 安源医药科技（上海）有限公司 | 针对tfpi的单克隆抗体及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2334107A1 (fr) * | 1975-12-05 | 1977-07-01 | Pasteur Institut | Procede de couplage de substances biologiques par des liaisons covalentes |
| US5589359A (en) | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| EP2379599B1 (en) * | 2008-12-22 | 2015-09-02 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor (tfpi) |
| AU2014200227A1 (en) | 2008-12-22 | 2014-01-30 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| US8361469B2 (en) * | 2008-12-22 | 2013-01-29 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| US8598327B2 (en) | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| US9260518B2 (en) | 2010-06-30 | 2016-02-16 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| SG193594A1 (en) * | 2011-04-01 | 2013-10-30 | Bayer Healthcare Llc | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| AU2013235741C1 (en) | 2012-03-21 | 2017-12-21 | Takeda Pharmaceutical Company Limited | TFPI inhibitors and methods of use |
| WO2013142153A2 (en) | 2012-03-22 | 2013-09-26 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
| CN104185474B (zh) | 2012-03-30 | 2017-08-25 | 拜尔健康护理有限责任公司 | 蛋白酶调节的抗体 |
| US10457743B2 (en) * | 2013-07-19 | 2019-10-29 | Novo Nordisk A/S | Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
-
2015
- 2015-09-17 CN CN201580050660.3A patent/CN106687482B/zh active Active
- 2015-09-17 WO PCT/EP2015/071359 patent/WO2016042093A1/en not_active Ceased
- 2015-09-17 EP EP15763621.8A patent/EP3194447B1/en active Active
- 2015-09-17 JP JP2017514888A patent/JP6783754B2/ja active Active
- 2015-09-17 US US15/508,229 patent/US11279771B2/en active Active
- 2015-09-17 ES ES15763621T patent/ES2905085T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532313A5 (enExample) | ||
| JP2020500538A5 (enExample) | ||
| CL2019001756A1 (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| JP2015508762A5 (enExample) | ||
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| HRP20171472T1 (hr) | Optimizirana monoklonska protutijela protiv inhibitora puta tkivnog faktora (tfpi) | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| PE20191131A1 (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos | |
| JP2017113028A5 (enExample) | ||
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| JP2017529097A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| AR081556A1 (es) | Proteinas de union al antigeno humanizadas | |
| JP2012509881A5 (enExample) | ||
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| JP2017522903A5 (enExample) | ||
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| FI2691417T4 (fi) | Vasta-aineen Fc-variantteja | |
| PE20221263A1 (es) | Agentes de union a ilt3 y metodos de uso de los mismos | |
| RU2017104642A (ru) | Новое антитело против tie-2 человека |